Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Armstrong AJ, Iguchi T, Azad AA, Villers A, Alekseev B, Petrylak DP, Szmulewitz RZ, Alcaraz A, Shore ND, Holzbeierlein J, Gomez-Veiga F, Rosbrook B, Zohren F, Haas GP, Gourgiotti G, El-Chaar N, Stenzl A. Armstrong AJ, et al. Among authors: azad aa. Eur Urol. 2023 Aug;84(2):229-241. doi: 10.1016/j.eururo.2023.04.002. Epub 2023 May 12. Eur Urol. 2023. PMID: 37179240 Free article. Clinical Trial.
Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
To SQ, Kwan EM, Fettke HC, Mant A, Docanto MM, Martelotto L, Bukczynska P, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenhöfer T, Azad AA. To SQ, et al. Among authors: azad aa. Eur Urol. 2018 Jun;73(6):818-821. doi: 10.1016/j.eururo.2018.01.007. Eur Urol. 2018. PMID: 29398263
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.
Kwan EM, Fettke H, Docanto MM, To SQ, Bukczynska P, Mant A, Pook D, Ng N, Graham LK, Mangiola S, Segelov E, Mahon K, Davis ID, Parente P, Pezaro C, Todenhöfer T, Horvath LG, Azad AA. Kwan EM, et al. Among authors: azad aa. Eur Urol Focus. 2021 Jan;7(1):63-70. doi: 10.1016/j.euf.2019.04.020. Epub 2019 May 15. Eur Urol Focus. 2021. PMID: 31103601
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H, Kwan EM, Docanto MM, Bukczynska P, Ng N, Graham LK, Mahon K, Hauser C, Tan W, Wang XH, Zhao Z, Zheng T, Zhou K, Du P, Yu J, Huang Y, Jia S, Kohli M, Horvath LG, Azad AA. Fettke H, et al. Among authors: azad aa. Eur Urol. 2020 Aug;78(2):173-180. doi: 10.1016/j.eururo.2020.03.044. Epub 2020 May 30. Eur Urol. 2020. PMID: 32487321 Free PMC article.
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
Azad AA, Armstrong AJ, Alcaraz A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Azad AA, et al. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):274-282. doi: 10.1038/s41391-021-00436-y. Epub 2021 Aug 21. Prostate Cancer Prostatic Dis. 2022. PMID: 34420037 Clinical Trial.
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
Kwan EM, Spain L, Anton A, Gan CL, Garrett L, Chang D, Liow E, Bennett C, Zheng T, Yu J, Dai C, Du P, Jia S, Fettke H, Abou-Seif C, Kothari G, Shaw M, Parente P, Pezaro C, Tran B, Siva S, Azad AA. Kwan EM, et al. Among authors: azad aa. Eur Urol. 2022 Mar;81(3):253-262. doi: 10.1016/j.eururo.2021.08.011. Epub 2021 Sep 4. Eur Urol. 2022. PMID: 34493414 Clinical Trial.
167 results